Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol

[1]  Rachel Churchill,et al.  Mirtazapine versus other antidepressive agents for depression. , 2010, The Cochrane database of systematic reviews.

[2]  N. Freemantle,et al.  Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review , 2010, Journal of psychopharmacology.

[3]  P. Blier,et al.  Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. , 2010, The American journal of psychiatry.

[4]  M. Fava,et al.  Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[5]  N. Titov,et al.  Clinician-Assisted Internet-Based Treatment is Effective for Panic: A Randomized Controlled Trial , 2009, The Australian and New Zealand journal of psychiatry.

[6]  J. Nelson,et al.  Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. , 2009, The American journal of psychiatry.

[7]  Mark S Levenson,et al.  Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration , 2009, BMJ : British Medical Journal.

[8]  N. Titov,et al.  Clinician-Assisted Internet-Based Treatment is Effective for Depression: Randomized Controlled Trial , 2009, The Australian and New Zealand journal of psychiatry.

[9]  Jingwei Wu,et al.  Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. , 2009, JAMA.

[10]  Nancy A Perrin,et al.  Collaborative care for chronic pain in primary care: a cluster randomized trial. , 2009, JAMA.

[11]  J. Geddes,et al.  Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis , 2009, The Lancet.

[12]  Rachel Churchill,et al.  Sertraline versus other antidepressive agents for depression. , 2009, The Cochrane database of systematic reviews.

[13]  D. Owens,et al.  Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. , 2008, Annals of internal medicine.

[14]  K. Lohr,et al.  Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians , 2008, Annals of Internal Medicine.

[15]  G. Andersson,et al.  Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. , 2008, The Journal of clinical psychiatry.

[16]  T. Furukawa,et al.  Adequacy of continuation and maintenance treatments for major depression in Japan , 2008, Journal of psychopharmacology.

[17]  R. Rosenthal,et al.  Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.

[18]  T. B. Üstün,et al.  Twelve-month prevalence, severity, and treatment of common mental disorders in communities in Japan: the World Mental Health Japan 2002-2004 survey. , 2008 .

[19]  Ronald C. Kessler,et al.  The WHO world mental health surveys: global perspectives on the epidemiology of mental disorders. , 2008 .

[20]  Kumiko Muramatsu,et al.  The Patient Health Questionnaire, Japanese Version: Validity According to the Mini-International Neuropsychiatric Interview–Plus , 2007, Psychological reports.

[21]  T. Furukawa,et al.  Long-Term Treatment of Depression with Antidepressants: A Systematic Narrative Review , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[22]  M. Oquendo,et al.  Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. , 2007, The American journal of psychiatry.

[23]  N. Crossley,et al.  Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. , 2007, The Journal of clinical psychiatry.

[24]  G. Guyatt,et al.  Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. , 2007, JAMA.

[25]  A. Schene,et al.  Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. , 2006, The Journal of clinical psychiatry.

[26]  A. Schene,et al.  Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder , 2006, British Journal of Psychiatry.

[27]  B. Lebowitz,et al.  Medication augmentation after the failure of SSRIs for depression. , 2006, The New England journal of medicine.

[28]  Maurizio Fava,et al.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. , 2006, The New England journal of medicine.

[29]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[30]  Antoni Serrano-Blanco,et al.  Assessing depression in primary care with the PHQ-9: Can it be carried out over the telephone? , 2005, Journal of General Internal Medicine.

[31]  T. Furukawa,et al.  Gradations of clinical severity and sensitivity to change assessed with the Beck Depression Inventory-II in Japanese patients with depression , 2005, Psychiatry Research.

[32]  A. Heinz,et al.  Is dose escalation of antidepressants a rational strategy after a medium–dose treatment has failed? , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[33]  J. Unützer,et al.  Monitoring Depression Treatment Outcomes With the Patient Health Questionnaire-9 , 2004, Medical care.

[34]  C. Barbui,et al.  Are we going to increase the use of antidepressants up to that of benzodiazepines? , 2004, European Journal of Clinical Pharmacology.

[35]  F. Mazzi,et al.  Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project , 2004, Acta psychiatrica Scandinavica. Supplementum.

[36]  Thomas R Ten Have,et al.  Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. , 2004, JAMA.

[37]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[38]  D. Kupfer,et al.  Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review , 2003, The Lancet.

[39]  Riccardo Torta,et al.  Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. , 2002, The Journal of clinical psychiatry.

[40]  S. Qvitzau,et al.  Treatment strategies in patients with major depression not responding to first-line sertraline treatment , 2002, Psychopharmacology.

[41]  L. Price,et al.  A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine , 2002, Biological Psychiatry.

[42]  L. Price,et al.  A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. , 2002, Biological psychiatry.

[43]  Anxiety Treatments.  Clinical guidelines for the treatment of depressive disorders. , 2001, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[44]  R A Steer,et al.  Mean Beck Depression Inventory–II Scores by Severity of Major Depressive Episode , 2001, Psychological reports.

[45]  A. Puech,et al.  Benefits from mianserin augmentation of fluoxetine in patients with major depression non‐responders to fluoxetine alone , 2001, Acta psychiatrica Scandinavica.

[46]  R. Spitzer,et al.  The PHQ-9: validity of a brief depression severity measure. , 2001, Journal of general internal medicine.

[47]  G. Grobler.  Clinical guidelines for the treatment of depressive disorders. , 2001, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[48]  E. Corruble,et al.  Does increasing dose improve efficacyin patients with poor antidepressantresponse: a review , 2000, Acta psychiatrica Scandinavica.

[49]  C. Sherbourne,et al.  Impact of disseminating quality improvement programs for depression in managed primary care: a randomized controlled trial. , 2000, JAMA.

[50]  J. Markowitz,et al.  Background information and treatment recommendations for patients with HIV/AIDS , 2000 .

[51]  J. Markowitz,et al.  Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. , 2000, The American journal of psychiatry.

[52]  R. Spitzer,et al.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. , 1999, JAMA.

[53]  Shan-Chwen Chang,et al.  From effect size into number needed to treat , 1999, The Lancet.

[54]  M. Meurisse,et al.  Liver transplantation in a Jehovah's witness , 1999, The Lancet.

[55]  T. Furukawa.  From effect size into number needed to treat , 1999, The Lancet.

[56]  C. Naylor,et al.  Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. , 1996, Archives of general psychiatry.

[57]  Jacob Cohen.  Statistical Power Analysis , 1992 .

[58]  A. Beck,et al.  Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation , 1988 .